<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Tarantelli, Chiara</dc:creator>
  <dc:creator>Bertoni, Francesco</dc:creator>
  <dc:date>2022</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Polatuzumab vedotin is antibody-drug conjugate (ADC) targeting CD79B approved for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma when given in combination with bendamustine and rituximab. The report by Kawasaki et al. provide hints on what might be happening in lymphoma cells exposed to polatuzumab vedotin and to rituximab and on potential mechanism of resistance to the ADC.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://susi.usi.ch/global/documents/322803</dc:identifier>
  <dc:identifier>https://localhost:5000/ark:/12658/srd1322803</dc:identifier>
  <dc:identifier>https://susi.usi.ch/documents/322803/files/Bertoni_2022_Wiley_bjhaem.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1111/bjh.18384</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/ark/12658/srd1322803</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>CC BY-NC-ND</dc:rights>
  <dc:source>British Journal of Haematology. - 2022, vol. 199, p. 169–170</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Antibody-drug conjugate</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Lymphoma</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">MMAE</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Polatuzumab vedotin</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Resistance</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Rituximab</dc:subject>
  <dc:subject>info:eu-repo/classification/udc/61</dc:subject>
  <dc:title xmlns:ns7="xml" ns7:lang="en">United we stand : double targeting of CD79B and CD20 in diffuse large B-cell lymphoma</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>